No Data
No Data
Ned Davis Research Compares Market's Reaction to Trump's 2016 & 2024 Victories
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Spotlight on AbbVie: Analyzing the Surge in Options Activity
10 Health Care Stocks With Whale Alerts In Today's Session
Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR
How Is The Market Feeling About Thermo Fisher Scientific?